{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:50:02Z","timestamp":1791589802160,"version":"4.3.4"},"reference-count":32,"publisher":"Universa BV","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Gut dysbiosis is linked with the pathophysiology of irritable\nbowel syndrome (IBS). Manipulation of intestinal microbiota using\ncultured milk drinks may stimulate the immune system, hence\nproviding beneficial support in IBS treatment. This study aimed to\ninvestigate the effects of cultured milk drink on clinical symptoms,\nintestinal transit time (ITT), fecal pH and cytokines in constipation-\npredominant IBS (IBS-C) as compared to non-IBS participants.\nEach recruited participant was given three bottles of 125 ml cultured\nmilk drink containing 10 9 cfu Lactobacillus acidophilus LA-5\nand Lactobacillus paracasei L. CASEI-01 consumed daily for 30\ndays. At pre- and post-30-day consumption, fecal pH, ITT, clinical\nsymptoms, IL-6, IL-8 and TNF-\u03b1 levels were assessed. Seventy-\nseven IBS-C and 88 non-IBS were enrolled. Post-consumption,\n97.4% of IBS-C experienced improvements in constipation-\nrelated symptoms supported by the significant reduction of ITT\nand decreased fecal pH (p&lt;0.05). All pro-inflammatory cytokines\nwere significantly lower in post as compared to pre-consumption\nof cultured milk drinks in IBS-C (p&lt;0.05). There was significant\nreduction in the IL-8 and TNF-\u03b1 levels in post- as compared to\npre-consumption for the non-IBS (p &lt; 0.05). Cultured milk drink\ntaken daily improved clinical symptoms and reduced cytokines,\nhence should be considered as an adjunctive treatment in IBS-C\nindividuals.<\/jats:p>","DOI":"10.51821\/84.4.009","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T15:20:17Z","timestamp":1637767217000},"page":"585-591","source":"Crossref","is-referenced-by-count":16,"title":["Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink"],"prefix":"10.51821","volume":"84","author":[{"given":"N.M.","family":"Mokhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.Md.","family":"Jaafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Alfian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.D.","family":"Mohd Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Abdul Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Raja Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27062","published-online":{"date-parts":[[2021,11]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"GIBSON, G.R., R.J. BRUMMER, E. ISOLAURI, H. LOCHS, L. MORELLI, T. OCKHUIZEN, et al., The design of probiotic studies to substantiate health claims. Gut Microbes, 2011. 2(5): 299-305.","DOI":"10.4161\/gmic.2.5.18002"},{"key":"ref1","unstructured":"DROSSMAN, D.A., D.L. DUMITRASCU, Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis, 2006. 15(3): 237-41."},{"key":"ref2","unstructured":"ROME, F., Guidelines--Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. J Gastrointestin Liver Dis, 2006. 15(3): 307-12."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"LONGSTRETH, G.F., W.G. THOMPSON, W.D. CHEY, L.A. HOUGHTON, F. MEARIN, R.C. SPILLER, Functional bowel disorders. Gastroenterology, 2006. 130(5): 1480-91.","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"LEE, Y.Y., A. WAID, H.J. TAN, A.S. CHUA, W.E. WHITEHEAD, Rome III survey of irritable bowel syndrome among ethnic Malays. World J Gastroenterol, 2012. 18(44): 6475-80; discussion p 9.","DOI":"10.3748\/wjg.v18.i44.6475"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"RAJENDRA, S., S. ALAHUDDIN, Prevalence of irritable bowel syndrome in a multi-ethnic Asian population. Aliment Pharmacol Ther, 2004. 19(6): 704-6.","DOI":"10.1111\/j.1365-2036.2004.01891.x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"TAN, Y.M., K.L. GOH, R. MUHIDAYAH, C.L. OOI, O. SALEM, Prevalence of irritable bowel syndrome in young adult Malaysians: a survey among medical students. J Gastroenterol Hepatol, 2003. 18(12): 1412-6.","DOI":"10.1046\/j.1440-1746.2003.03212.x"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"NAM, S.Y., B.C. KIM, K.H. RYU, B.J. PARK, Prevalence and risk factors of irritable bowel syndrome in healthy screenee undergoing colonoscopy and laboratory tests. J Neurogastroenterol Motil, 2010. 16(1): 47-51.","DOI":"10.5056\/jnm.2010.16.1.47"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"KASSINEN, A., L. KROGIUS-KURIKKA, H. MAKIVUOKKO, T. RINTTILA, L. PAULIN, J. CORANDER, et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology, 2007. 133(1): 24-33.","DOI":"10.1053\/j.gastro.2007.04.005"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"KERCKHOFFS, A.P., M. SAMSOM, M.E. VAN DER REST, J. DE VOGEL, J. KNOL, K. BEN-AMOR, et al., Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol, 2009. 15(23): 2887-92.","DOI":"10.3748\/wjg.15.2887"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"FARZAEI, M.H., R. BAHRAMSOLTANI, M. ABDOLLAHI, R. RAHIMI, The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J Neurogastroenterol Motil, 2016. 22(4): 558-74.","DOI":"10.5056\/jnm16001"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"MORELLI, L., L. CAPURSO, FAO\/WHO guidelines on probiotics: 10 years later. J Clin Gastroenterol, 2012. 46 Suppl: S1-2.","DOI":"10.1097\/mcg.0b013e318269fdd5"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"OLIVARES, M., M.A. DIAZ-ROPERO, N. GOMEZ, F. LARAVILLOSLADA, S. SIERRA, J.A. MALDONADO, et al., Oral administration of two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, enhances the intestinal function of healthy adults. Int J Food Microbiol, 2006. 107(2): 104-11.","DOI":"10.1016\/j.ijfoodmicro.2005.08.019"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"O\u2019MAHONY, L., J. MCCARTHY, P. KELLY, G. HURLEY, F. LUO, K. CHEN, et al., Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology, 2005. 128(3): 541-51.","DOI":"10.1053\/j.gastro.2004.11.050"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"HAN, X., A. LEE, S. HUANG, J. GAO, J.R. SPENCE, C. OWYANG, Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids. Gut Microbes, 2019. 10(1): 59-76.","DOI":"10.1080\/19490976.2018.1479625"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"LIEBREGTS, T., B. ADAM, C. BREDACK, A. ROTH, S. HEINZEL, S. LESTER, et al., Immune activation in patients with irritable bowel syndrome. Gastroenterology, 2007. 132(3): 913-20.","DOI":"10.1053\/j.gastro.2007.01.046"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"DINAN, T.G., E.M. QUIGLEY, S.M. AHMED, P. SCULLY, S. O\u2019BRIEN, L. O\u2019MAHONY, et al., Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastro- enterology, 2006. 130(2): 304-11.","DOI":"10.1053\/j.gastro.2005.11.033"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"SEYEDMIRZAEE, S., M.M. HAYATBAKHSH, B. AHMADI, N. BANIASADI, A.M. BAGHERI RAFSANJANI, A.R. NIKPOOR, et al., Serum immune biomarkers in irritable bowel syndrome. Clin Res Hepatol Gastroenterol, 2016. 40(5): 631-7.","DOI":"10.1016\/j.clinre.2015.12.013"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"BASHASHATI, M., M. MORADI, I. SAROSIEK, Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels. Cytokine, 2017. 99: 132-8.","DOI":"10.1016\/j.cyto.2017.08.017"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"DUPONT, W.D., W.D. PLUMMER, JR., Power and sample size calculations. A review and computer program. Control Clin Trials, 1990. 11(2): 116-28.","DOI":"10.1016\/0197-2456(90)90005-M"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"CAMILLERI, M., D.R. LINDEN, Measurement of Gastrointestinal and Colonic Motor Functions in Humans and Animals. Cell Mol Gastroenterol Hepatol, 2016. 2(4): 412-28.","DOI":"10.1016\/j.jcmgh.2016.04.003"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"GARRIGUES, V., C. GALVEZ, V. ORTIZ, M. PONCE, P. NOS, J. PONCE, Prevalence of constipation: agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a population-based survey in Spain. Am J Epidemiol, 2004. 159(5): 520-6.","DOI":"10.1093\/aje\/kwh072"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"GWEE, K.A., W.W. LEE, K.L. LING, C.J. OOI, S.H. QUAK, Y.Y. DAN, et al., Consensus and contentious statements on the use of probiotics in clinical practice: A south east Asian gastro-neuro motility association working team report. J Gastroenterol Hepatol, 2018. 33(10): 1707-16.","DOI":"10.1111\/jgh.14268"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"BOGOVIC MATIJASIC, B., T. OBERMAJER, L. LIPOGLAVSEK, T. SERNEL, I. LOCATELLI, M. KOS, et al., Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial. J Dairy Sci, 2016. 99(7): 5008-21.","DOI":"10.3168\/jds.2015-10743"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"AGRAWAL, A., L.A. HOUGHTON, J. MORRIS, B. REILLY, D. GUYONNET, N. GOUPIL FEUILLERAT, et al., Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther, 2009. 29(1): 104-14.","DOI":"10.1111\/j.1365-2036.2008.03853.x"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"KOEBNICK, C., I. WAGNER, P. LEITZMANN, U. STERN, H.J. ZUNFT, Probiotic beverage containing Lactobacillus casei Shirota improves gastro-intestinal symptoms in patients with chronic constipation. Can J Gastro-enterol, 2003. 17(11): 655-9.","DOI":"10.1155\/2003\/654907"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"RINGEL-KULKA, T., C.H. CHOI, D. TEMAS, A. KIM, D.M. MAIER, K. SCOTT, et al., Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome. Am J Gastroenterol, 2015. 110(9): 1339-46.","DOI":"10.1038\/ajg.2015.220"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"BAHRUDIN, M.F., R. ABDUL RANI, A.M. TAMIL, N.M. MOKHTAR, R.A. RAJA ALI, Effectiveness of Sterilized Symbiotic Drink Containing Lactobacillus helveticus Comparable to Probiotic Alone in Patients with Constipation-Predominant Irritable Bowel Syndrome. Dig Dis Sci, 2020. 65(2): 541-9.","DOI":"10.1007\/s10620-019-05695-3"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"TORNBLOM, H., L. VAN OUDENHOVE, R. SADIK, H. ABRAHAMSSON, J. TACK, M. SIMREN, Colonic transit time and IBS symptoms: what\u2019s the link? Am J Gastroenterol, 2012. 107(5): 754-60.","DOI":"10.1038\/ajg.2012.5"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"SALMINEN, S., S. NYBOM, J. MERILUOTO, M.C. COLLADO, S. VESTERLUND, H. EL-NEZAMI, Interaction of probiotics and pathogens-benefits to human health? Curr Opin Biotechnol, 2010. 21(2): 157-67.","DOI":"10.1016\/j.copbio.2010.03.016"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"DINAN, T.G., G. CLARKE, E.M. QUIGLEY, L.V. SCOTT, F. SHANAHAN, J. CRYAN, et al., Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol, 2008. 103(10): 2570-6.","DOI":"10.1111\/j.1572-0241.2008.01871.x"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"DIDARI, T., S. MOZAFFARI, S. NIKFAR, M. ABDOLLAHI, Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol, 2015. 21(10): 3072-84.","DOI":"10.3748\/wjg.v21.i10.3072"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T15:31:56Z","timestamp":1644852716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/1957\/Clinical%20assessment%20and%20cytokines%20level%20in%20constipation-predominant%20irritablebowel%20syndrome%20participants%20treated%20with%20Lactobacillus-containing%20culturedmilk%20drink\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,10]]},"published-print":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.51821\/84.4.009","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}